Drugs / XELAFASLATIDE
XELAFASLATIDE
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05160805 | May 2022 → Apr 2024 | open-angle glaucoma | ONL Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04744662 | Jul 2021 → Feb 2024 | diffuse secondary choroid atrophy | ONL Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06659445 | Oct 2025 → Nov 2028 expected | dry age related macular degeneration | ONL Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05730218 | Apr 2023 → Feb 2024 | rhegmatogenous retinal detachment | ONL Therapeutics | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03780972 Comparator | Oct 2019 → Aug 2021 | rhegmatogenous retinal detachment | ONL Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XELAFASLATIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068318 ↗ |
| Known as | ONL1204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05160805 ↗ |
| Known as | Xelafaslatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068318 ↗ |
| Action | Inhibit | “inhibitor of Fas(CD95) signaling” NCT03780972 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068318 ↗ |
| Route | Intravitreal | “by intravitreal injection” NCT03780972 ↗ |